Cargando…

Understanding clinician perspectives on antibiotic associated adverse events to inform feedback

Background: Feedback regarding antibiotic-associated adverse events (ABX-AEs) may assist clinicians with antibiotic decision making. We sought to understand how clinicians account for ABX-AEs when prescribing and their preferences for ABX-AE feedback. Methods: We conducted 1-hour virtual focus group...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherian, Jerald, Jones, George, Helsel, Taylor, Virk, Zunaira, Salinas, Alejandra, Grieb, Suzanne, Keller, Sara, Tamma, Pranita, Cosgrove, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594371/
http://dx.doi.org/10.1017/ash.2023.265
_version_ 1785124635101102080
author Cherian, Jerald
Jones, George
Helsel, Taylor
Virk, Zunaira
Salinas, Alejandra
Grieb, Suzanne
Keller, Sara
Tamma, Pranita
Cosgrove, Sara
author_facet Cherian, Jerald
Jones, George
Helsel, Taylor
Virk, Zunaira
Salinas, Alejandra
Grieb, Suzanne
Keller, Sara
Tamma, Pranita
Cosgrove, Sara
author_sort Cherian, Jerald
collection PubMed
description Background: Feedback regarding antibiotic-associated adverse events (ABX-AEs) may assist clinicians with antibiotic decision making. We sought to understand how clinicians account for ABX-AEs when prescribing and their preferences for ABX-AE feedback. Methods: We conducted 1-hour virtual focus groups with 3–5 physicians or advance practice practitioners (APPs) per session at Johns Hopkins Hospital. Participants discussed the role of ABX-AEs in antibiotic decision making and feedback preferences. Participants evaluated prespecified categorization (mildly, moderately, or very concerning) of several ABX-AEs. Focus groups were recorded and transcribed. Transcripts were coded inductively by 2 independent reviewers; discrepancies were resolved by consensus. Codes were used to conduct thematic analysis. Results: Overall, 3 focus groups were conducted with 12 participants: 41.6% were house staff, 16.7% were attending physicians, and 41.6% were APPs. Most were female (91.6%) and were white (41.7%) or Asian (41.7%). Clinicians generally agreed with the prespecified categorizations of ABX-AEs based on degree of clinical concern (Table). We identified 5 themes: (1) The risk of ABX-AE is considered during initial prescribing but influences agent selection more than the decision to prescribe antibiotics. (2) The occurrence of an ABX-AE leads to assessment of need for continued antibiotic therapy. (3) The impact of an ABX-AE on other management decisions is as important as the direct harm of the ABX-AE when assessing severity. (4) Feedback must be curated to prevent clinicians from being overwhelmed with data. (5) Clinicians will be more receptive to feedback regarding ABX-AEs if feedback is contextualized (Fig.). Conclusions: The themes identified and assessment of ABX-AEs of greatest clinical concern may help inform the development of effective ABX-AE feedback methods to improve antibiotic safety. Disclosures: None
format Online
Article
Text
id pubmed-10594371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105943712023-10-25 Understanding clinician perspectives on antibiotic associated adverse events to inform feedback Cherian, Jerald Jones, George Helsel, Taylor Virk, Zunaira Salinas, Alejandra Grieb, Suzanne Keller, Sara Tamma, Pranita Cosgrove, Sara Antimicrob Steward Healthc Epidemiol Antibiotic Stewardship Background: Feedback regarding antibiotic-associated adverse events (ABX-AEs) may assist clinicians with antibiotic decision making. We sought to understand how clinicians account for ABX-AEs when prescribing and their preferences for ABX-AE feedback. Methods: We conducted 1-hour virtual focus groups with 3–5 physicians or advance practice practitioners (APPs) per session at Johns Hopkins Hospital. Participants discussed the role of ABX-AEs in antibiotic decision making and feedback preferences. Participants evaluated prespecified categorization (mildly, moderately, or very concerning) of several ABX-AEs. Focus groups were recorded and transcribed. Transcripts were coded inductively by 2 independent reviewers; discrepancies were resolved by consensus. Codes were used to conduct thematic analysis. Results: Overall, 3 focus groups were conducted with 12 participants: 41.6% were house staff, 16.7% were attending physicians, and 41.6% were APPs. Most were female (91.6%) and were white (41.7%) or Asian (41.7%). Clinicians generally agreed with the prespecified categorizations of ABX-AEs based on degree of clinical concern (Table). We identified 5 themes: (1) The risk of ABX-AE is considered during initial prescribing but influences agent selection more than the decision to prescribe antibiotics. (2) The occurrence of an ABX-AE leads to assessment of need for continued antibiotic therapy. (3) The impact of an ABX-AE on other management decisions is as important as the direct harm of the ABX-AE when assessing severity. (4) Feedback must be curated to prevent clinicians from being overwhelmed with data. (5) Clinicians will be more receptive to feedback regarding ABX-AEs if feedback is contextualized (Fig.). Conclusions: The themes identified and assessment of ABX-AEs of greatest clinical concern may help inform the development of effective ABX-AE feedback methods to improve antibiotic safety. Disclosures: None Cambridge University Press 2023-09-29 /pmc/articles/PMC10594371/ http://dx.doi.org/10.1017/ash.2023.265 Text en © The Society for Healthcare Epidemiology of America 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Antibiotic Stewardship
Cherian, Jerald
Jones, George
Helsel, Taylor
Virk, Zunaira
Salinas, Alejandra
Grieb, Suzanne
Keller, Sara
Tamma, Pranita
Cosgrove, Sara
Understanding clinician perspectives on antibiotic associated adverse events to inform feedback
title Understanding clinician perspectives on antibiotic associated adverse events to inform feedback
title_full Understanding clinician perspectives on antibiotic associated adverse events to inform feedback
title_fullStr Understanding clinician perspectives on antibiotic associated adverse events to inform feedback
title_full_unstemmed Understanding clinician perspectives on antibiotic associated adverse events to inform feedback
title_short Understanding clinician perspectives on antibiotic associated adverse events to inform feedback
title_sort understanding clinician perspectives on antibiotic associated adverse events to inform feedback
topic Antibiotic Stewardship
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594371/
http://dx.doi.org/10.1017/ash.2023.265
work_keys_str_mv AT cherianjerald understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT jonesgeorge understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT helseltaylor understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT virkzunaira understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT salinasalejandra understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT griebsuzanne understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT kellersara understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT tammapranita understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback
AT cosgrovesara understandingclinicianperspectivesonantibioticassociatedadverseeventstoinformfeedback